Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A3CH
|
|||
| Drug Name |
GRN-1201
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 2 | [1] | |
| Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 1 | [2], [3], [4] | ||
| Merkel cell carcinoma [ICD-11: 2C34; ICD-10: C44] | Phase 1 | [2], [3], [4] | ||
| Company |
BrightPath Biotherapeutics Tokyo, Japan
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03417882) GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.